Literature DB >> 19395273

Percutaneous treatment of idiopathic chylopericardium.

Hans H Schild1, Birgit Simon, Christiane K Kuhl, Michael Nelles, Reiner Koerfer, Dirk Skowasch, Stefanie Kuntz-Hehner, Michael Haude.   

Abstract

Chylopericardium is a rare disease that may result from a variety of causes, such as cardiac surgery, trauma, obstruction of the thoracic duct near its drainage into the subclavian vein, or have no identifiable underlying cause. The present report describes a case of idiopathic chylopericardium in which percutaneous transabdominal occlusion of the thoracic duct was performed as an alternative to surgical duct ligation. The procedure was successful, resulting in a decrease in pericardial fluid accumulation. However, it failed to cure the patient, as constrictive pericarditis developed 2 months later, requiring surgical pericardectomy. Whether this could have been avoided by early (percutaneous) pericardial fenestration is unknown.

Entities:  

Mesh:

Year:  2009        PMID: 19395273     DOI: 10.1016/j.jvir.2009.02.011

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  4 in total

1.  Primary chylopericardium: A case report and literature review.

Authors:  Xue Yu; Na Jia; Sanxia Ye; Min Zhou; Deping Liu
Journal:  Exp Ther Med       Date:  2017-10-27       Impact factor: 2.447

2.  Primary idiopathic chylopericardium: a retrospective case series.

Authors:  Zhijun Han; Shanqing Li; Hongli Jing; Hongsheng Liu
Journal:  BMC Surg       Date:  2015-05-12       Impact factor: 2.102

3.  Pediatric Chylopericardium: Treatment Conundrum.

Authors:  Mitul Jasani; Amar Shah; Anirudh V Shah
Journal:  J Indian Assoc Pediatr Surg       Date:  2018 Jan-Mar

4.  A medical epopee: recurrent fungal endocarditis, heart transplantation and chylopericardium.

Authors:  Antonio de Santis; Guilherme Moratti Gilberto; Sandrigo Mangini; Adalberto Batalha Megale; Fabio Antonio Gaiotto; Ricardo Mingarini Terra; Rodrigo Gobbo Garcia
Journal:  BMC Cardiovasc Disord       Date:  2020-10-31       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.